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Conventional drugs often have poor pharmacokinetics and biopharmaceutical properties[1]. 
Whereas, nanosized drug delivery systems may prolong shelf-life and enhance bioavailability 
and acceptability by increasing either uptake efficacy or patient compliance [2].  
TNTs were synthetized with hydrothermal method, and then composites were formed with 
atenolol (ATN) and hydrochlorothiazide (HCT) using various solvents. Ethanol, methanol and 
0.01M HCl solution or ethanol and 1M NaOH solution were used to produce TiATN and TiHCT 
composites respectively. The physicochemical properties of the samples were investigated by 
using TEM (FEI, OR, USA) and SEM (Hitachi, Japan) imaging to analyze the texture, optical 
contact angle tester (DataPhysics, Germany) to determine the surface free energy, FT-IR 
spectrometer (Thermo Fisher Scientific Ltd., MA, USA) and DSC/TG apparatus (Mettler-Toledo 
Ltd, Hungary) to detect the interaction between drugs and TNTs. 
The results revealed that the strength of interactions is highly connected to the solubility of 
the drug in , and to the volatility of the applied solvent. Moreover, the strength of interactions 
exhibited considerable influence on the surface characteristics of the products, which 
determines their processability and their behaviour in biological environment. 
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